iXensor PixoTest POCT DADA2

PixoTest POCT DADA2 is designed to save lives right at the first onset of those children who suffer from the rare disease DADA2 as it is cumbersome and expensive to diagnose this rare disease in the current healthcare system. PixoTest POCT DADA2 can diagnose all those children arriving ERs with strokes in a timely fashion and affordable scheme to rule out other diseases. Then TNF inhibitors can be prescribed to prevent recurrent strokes that will leave irreversible impacts on children’s health.

Deficiency of adenosine deaminase 2 (DADA2) is a rare, autosomal recessive autoinflammatory disease that is caused by mutations in the ADA2 gene with 0.004% onset rate. DADA2 is usually a childhood-onset disease, with 24% of cases reported before 1 year of age, and 77% before the age of 10. Children who suffered from DADA2 usually had more than three strokes on average before they were correctly diagnosed. The current way to confirm the case is through time-consuming and expensive genome sequencing. iXensor's PixoTest POCT DADA2 tries to provide an alternative timely and affordable POCT solution at ER where most DADA2 children will be sent to when the disease manifests itself the first time through the stoke.

iXensor provides PixoTest POCT DADA2, a digital analyzer with rapid lateral flow assay for detecting ADA activity at point-of-care setting, especially at ER. It can generate quantitative results in 15 minutes by trained healthcare professionals with finger-prick blood.

PixoTest POCT DADA2 serve to diagnose the complicated rare disease DADA2 patients whose disease manifest in multiple system inflammation and vasculopathy that affects a wide variety of organs. These patients needed to be diagnosed at their diseases' very first onsets; otherwise most of them will suffer from recurrent strokes in early ages. With correct diagnoses, the TNF inhibitor can heal them as early as possible and prevent them from further inflammations and strokes.

Confronting pandemic, everyone has equal right to be protected from the contagious virus, however for those undiagnosed rare disease patients, especially those who suffered from DADA2 with immunologic manifestations, their health security need to be established by diagnosing and treating their disease first. iXensor’s PixoTest POCT DADA2 can be deployed among children’s hospitals worldwide to challenge the status quo while building up the health security for those most vulnerable children before they can be inoculated.

iXensor’s PixoTest POCT DADA2 solution has been verified by the DADA2 Foundation and the feasibility study and lab experiment results were presented at the 3rd International Conference on Deficiency of Adenosine Deaminase 2 (DADA2), the CEO of iXensor, Dr. Carson Chen.  

Our solution is based on iXensor’s core technology PixoTech platform that transforms smartphones into medical diagnostic devices by controlling smartphones’ front camera and display lighting so as to leverage computer vision for analyzing later flow assay color changes and provide qualitative or quantitative results as the actionable data for timely intervention by healthcare professionals.

PixoTech® as iXensor’s core technology platform can turn smartphones into in vitro diagnostic (IVD) devices through its smart color sensing technology for connected healthcare. It utilizes the lighting and image sensing modules of the smartphone to detect the color change reaction on the immunoassay or colorimetric strip (US patent granted). The images of the test strip are captured by the front camera of the smartphone and analyzed via the proprietary algorithm to turn out a qualitative or semi-quantitative or quantitative result. With the control on light sources with multiple wavelengths from the screen lighting module of the smartphone, the PixoTech® algorithm can be easily customized to accommodate different biomarkers.

In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, and cardiovascular diseases.  www.ixensor.com

No, not to our current knowledge

We currently serve more than 50,000 people through our three products based on the PixoTech technology platform. We expect to serve another 500,000 people more through our latest PixoTest COVID-19 Antigen Test.

The goal for iXensor in 2022 is Partnerships for the Goals as we will licence out our technology to other test strip manufacturers or pharmaceutical partners so we can reach more people to help them improve lives through actionable data measured from at-home testing or point-of-care testings. 

1. number of people who use our solutions

2. cycle of repeated testing

3. Net Promotion Score (reflect the usefulness of our at-home testing solution)

Eleven full-time staff out of 40 employees

We are pioneers of mobile health. Our interdisciplinary team combines expertise in medical engineering, biochemistry, and information technology to develop innovative digital health solutions that empower tomorrow's connected healthcare. We have the main leadership team coming from pharmaceutical companies and ICT industries so we are well-positioned to identify unmet needs from the healthcare system and turn insights into the latest digital health solutions.

Our leadership team is composited by a group of experts representing different functional experts coming from both healthcare and information technology industries. We have female leaders represented 35 percent of the leadership team.

No

We need sufficient funding to continue our innovation and production so that we can bring a positive impact to the world where more people can benefit from our democratize approach of medical diagnostic in the context of accessible global healthcare with diagnostic as the last mile of telehealth.

Those companies regard diagnostic as the last mile of telehealth